ATE224911T1 - Gmp-140 ligand - Google Patents

Gmp-140 ligand

Info

Publication number
ATE224911T1
ATE224911T1 AT95202380T AT95202380T ATE224911T1 AT E224911 T1 ATE224911 T1 AT E224911T1 AT 95202380 T AT95202380 T AT 95202380T AT 95202380 T AT95202380 T AT 95202380T AT E224911 T1 ATE224911 T1 AT E224911T1
Authority
AT
Austria
Prior art keywords
gmp
alpha
sialyated
carbohydrate
structures
Prior art date
Application number
AT95202380T
Other languages
English (en)
Inventor
Rodger P Mcever
Original Assignee
Univ Oklahoma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Oklahoma filed Critical Univ Oklahoma
Application granted granted Critical
Publication of ATE224911T1 publication Critical patent/ATE224911T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596Molecules with a "CD"-designation not provided for elsewhere
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/16Central respiratory analeptics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056Lectin superfamily, e.g. CD23, CD72
    • C07K14/70564Selectins, e.g. CD62
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT95202380T 1990-07-17 1991-07-17 Gmp-140 ligand ATE224911T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55419990A 1990-07-17 1990-07-17
US65048491A 1991-02-05 1991-02-05

Publications (1)

Publication Number Publication Date
ATE224911T1 true ATE224911T1 (de) 2002-10-15

Family

ID=27070521

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95202380T ATE224911T1 (de) 1990-07-17 1991-07-17 Gmp-140 ligand

Country Status (9)

Country Link
EP (2) EP0544815A1 (de)
JP (5) JP3096305B2 (de)
AT (1) ATE224911T1 (de)
AU (2) AU660627B2 (de)
CA (1) CA2086323C (de)
DE (1) DE69133120T2 (de)
DK (1) DK0714912T3 (de)
ES (1) ES2183851T3 (de)
WO (1) WO1992001718A2 (de)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5800815A (en) * 1903-05-05 1998-09-01 Cytel Corporation Antibodies to P-selectin and their uses
US5464778A (en) * 1989-03-08 1995-11-07 Board Of Regents Of The University Of Oklahoma Glycoprotein ligand for P-selectin and methods of use thereof
DK0496832T3 (da) * 1989-10-20 1996-12-30 New England Medical Center Inc Inhibering af PADGEM-formidlet cellebinding
US6387884B1 (en) 1990-06-18 2002-05-14 Stanford University Leukocyte homing modulation
US6391857B1 (en) 1990-06-18 2002-05-21 Stanford University Methods and compositions for endothelial binding
NZ240316A (en) * 1990-10-25 1996-12-20 Univ Michigan Compound for treating disease mediated by the elaboration of elam-1 on endothelial cells
US6124267A (en) * 1991-02-05 2000-09-26 Southpac Trust Internationals, Inc. O-glycan inhibitors of selectin mediated inflammation derived from PSGL-1
US6309639B1 (en) 1991-02-05 2001-10-30 The Board Of Regents Of The University Of Oklahoma Method for inhibiting an inflammatory response using antibodies to P-selectin glycoprotein ligand
US5807745A (en) * 1991-03-11 1998-09-15 New England Medical Center Hospitals, Inc. Method of inhibiting PADGEM-mediated or ELAM-1-mediated leukocyte adhesion using an inhibitor comprising a Lex core component
EP0580763B1 (de) * 1991-04-19 2006-09-06 The Board Of Trustees Of The Leland Stanford Junior University Zusammensetzungen und methoden für die verknüpfung von endothelzellen
US6121233A (en) 1991-04-19 2000-09-19 John L. Magnani Methods for the inhibition of cancer metastasis mediated by endothelial adhesion molecules
EP0668871A1 (de) * 1991-05-03 1995-08-30 The Rockefeller University Homologien in der aminosaüre-sequenz zwischen peptiden der selectine und peptiden des b.pertussis-toxin, antikörper dagegen und pharmazeutische verbindungen
CA2103139A1 (en) * 1991-05-14 1992-11-15 George A. Heavner Peptide inhibitors of inflammation
US5646123A (en) * 1991-06-10 1997-07-08 Alberta Research Council Time dependent administration of oligosaccharide glycosides related to blood group determinants having a type I or type II core structure in reducing inflammation in a sensitized mammal arising form exposure to an antigen
WO1993005070A1 (en) * 1991-09-10 1993-03-18 Centocor, Inc. Peptide inhibitors of inflammation mediated by selectins
WO1993005803A1 (en) * 1991-09-25 1993-04-01 Genetics Institute, Inc. Anti-inflammatory selectin inhibitors
WO1994004568A1 (en) * 1991-12-18 1994-03-03 Centocor, Inc. Peptide inhibitors of inflammation mediated by selectins
DK0639224T3 (da) * 1992-04-30 2000-10-30 Genentech Inc Varianter i lectindomænet af selectin
CA2135083C (en) * 1992-05-05 2004-01-06 Robert W. Chestnut Antibodies to p-selectin and their uses
US6033667A (en) * 1992-05-05 2000-03-07 Cytel Corporation Method for detecting the presence of P-selectin
US5643873A (en) * 1992-05-06 1997-07-01 Affymax Technologies N.V. Peptides and compounds that bind selectins including endothelial leukocyte adhesion molecule 1
US5648458A (en) * 1992-05-06 1997-07-15 Affymax Technologies N.V. Peptides and compounds that bind to ELAM-1
US5728802A (en) * 1992-05-06 1998-03-17 Affymax Technologies N.V. Peptides and compounds that bind selectins including endothelium leukocyte adhesion molecule 1 (ELAM-1)
EP0656904A1 (de) * 1992-05-28 1995-06-14 Centocor Inc. Peptidinhibitoren für die selectin-bindung
CA2136428A1 (en) * 1992-05-28 1993-12-09 George A. Heavner Peptide inhibitors of selectin binding
US5440015A (en) * 1992-07-21 1995-08-08 Glycomed Incorporated Selectin peptide medicaments for treating disease
US5753617A (en) * 1992-09-08 1998-05-19 Centocor, Inc. Peptide inhibitors of cellular adhesion
ATE210452T1 (de) 1992-10-02 2001-12-15 Alberta Res Council Entzündungshemmende tolerogene und immunoinhibitorische eigenschaften von karbohydrate bindende peptide
PT666914E (pt) * 1992-10-23 2004-04-30 Inst Genetics Llc Nova proteina ligando da selectina p
US6277975B1 (en) 1992-10-23 2001-08-21 Genetics Institute, Inc. Fusions of P-selectin ligand protein and polynucleotides encoding same
US5843707A (en) * 1992-10-23 1998-12-01 Genetics Institute, Inc. Nucleic acid encoding a novel P-selectin ligand protein
AU681369B2 (en) * 1992-11-16 1997-08-28 Board Of Regents Of The University Of Oklahoma, The Glycoprotein ligand for P-selectin and methods of use thereof
US5710123A (en) * 1992-12-18 1998-01-20 Centocor, Inc. Peptide inhibitors of selectin binding
US5976540A (en) * 1993-05-17 1999-11-02 T Cell Sciences, Inc. Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions
US5856300A (en) * 1994-05-12 1999-01-05 T Cell Sciences, Inc. Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions
DK0730608T3 (da) 1993-05-17 2002-07-22 Avant Immunotherapeutics Inc Præparater omfattende komplementrelaterede proteiner og carbohydrater og fremgangsmåder til fremstilling og anvendelse af præparaterne
US5750508A (en) * 1993-06-16 1998-05-12 Glycomed Incorporated Sialic acid/fucose based medicaments
WO1995014787A1 (en) * 1993-11-22 1995-06-01 Centocor, Inc. Peptide inhibitors of selecting binding
US5663151A (en) * 1994-03-04 1997-09-02 Bristol-Myers Squibb Company Sulfated α-glycolipid derivatives as cell adhesion inhibitors
CA2142153A1 (en) * 1994-03-04 1995-09-05 Jacques Banville Sulfated .beta.-glycolipid derivatives as cell adhesion inhibitors
WO1995030001A2 (en) * 1994-04-28 1995-11-09 Genetics Institute, Inc. Novel p-selectin ligand protein
US5686426A (en) * 1994-11-17 1997-11-11 Bristol-Myers Squibb Company Dicarboxymethylated glycolipid derivatives as cell adhesion inhibitors
CZ401497A3 (cs) * 1995-06-14 1998-07-15 The General Hospital Corporation P-selektinové ligandy a příbuzné molekuly a způsoby
US5747463A (en) * 1995-11-13 1998-05-05 Bristol-Myers Squibb Company Malonate derivatives of glycolipids as cell adhesion inhibitors
EP0909272B1 (de) 1996-06-10 2007-02-07 Borén, Thomas Adhesin aus heliobacter pylori, welches an blutgruppenantigene bindet
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
ATE348163T1 (de) 1998-10-23 2007-01-15 Amgen Inc Thrombopoietin substitute
JP5183010B2 (ja) 2002-05-16 2013-04-17 グリコミメティクス, インコーポレイテッド セレクチンによって媒介される機能を阻害するための化合物および方法
WO2005051920A2 (en) 2003-11-19 2005-06-09 Glycomimetics, Inc. Specific antagonist for both e- and p-selectins
JP2008505928A (ja) 2004-07-08 2008-02-28 アムジェン インコーポレーテッド 治療用ペプチド
DK1797127T3 (en) 2004-09-24 2017-10-02 Amgen Inc Modified Fc molecules
JP5175190B2 (ja) 2005-08-09 2013-04-03 グリコミメティクス, インコーポレイテッド シュードモナス由来のpa−ilレクチン、pa−iilレクチンまたは両方のレクチンのグリコミメティック阻害剤
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
US7728117B2 (en) 2005-09-02 2010-06-01 Glycomimetics, Inc. Heterobifunctional pan-selectin inhibitors
WO2009126556A1 (en) 2008-04-08 2009-10-15 Glycomimetics, Inc. Pan-selectin inhibitor with enhanced pharmacokinetic activity
US8921328B2 (en) 2010-09-14 2014-12-30 Glycomimetics, Inc. E-selectin antagonists
ES2655443T7 (es) 2011-12-22 2021-03-22 Glycomimetics Inc Compuestos antagonistas de E-selectina
LT2928476T (lt) 2012-12-07 2018-05-25 Glycomimetics, Inc. Junginiai, kompozicijos ir būdai, naudojant e-selektino antagonistus, hemopoetinių ląstelių mobilizacijai
ES2754549T3 (es) 2014-12-03 2020-04-20 Glycomimetics Inc Inhibidores heterobifuncionales de E-selectinas y receptores de quimioquinas CXCR4
US11045485B2 (en) 2016-01-22 2021-06-29 Glycomimetics, Inc. Glycomimetic inhibitors of PA-IL and PA-IIL lectins
WO2017151708A1 (en) 2016-03-02 2017-09-08 Glycomimetics, Inc. Methods for the treatment and/or prevention of cardiovescular disease by inhibition of e-selectin
WO2018031445A1 (en) 2016-08-08 2018-02-15 Glycomimetics, Inc. Combination of t-cell checkpoint inhibitors with inhibitors of e-selectin or cxcr4, or with heterobifunctional inhibitors of both e-selectin and cxcr4
KR20240046288A (ko) 2016-10-07 2024-04-08 글리코미메틱스, 인크. 매우 강력한 다량체성 e-셀렉틴 길항물질
EP3568159A4 (de) 2017-01-11 2020-08-05 Bristol-Myers Squibb Company Psgl-1-antagonisten und verwendung davon
KR20240151866A (ko) 2017-03-14 2024-10-18 파이브 프라임 테라퓨틱스, 인크. 산성 pH에서 VISTA에 결합하는 항체
US11197877B2 (en) 2017-03-15 2021-12-14 Glycomimetics. Inc. Galactopyranosyl-cyclohexyl derivauves as E-selectin antagonists
US11712446B2 (en) 2017-11-30 2023-08-01 Glycomimetics, Inc. Methods of mobilizing marrow infiltrating lymphocytes and uses thereof
US11548908B2 (en) 2017-12-29 2023-01-10 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectin and galectin-3
BR112020018184A2 (pt) 2018-03-05 2021-02-02 Glycomimetics, Inc. usos de compostos
PE20210290A1 (es) 2018-03-21 2021-02-11 Five Prime Therapeutics Inc ANTICUERPOS DE UNION A VISTA A pH ACIDO
EP3820902A2 (de) 2018-07-11 2021-05-19 Five Prime Therapeutics, Inc. An vista bei saurem ph-wert bindende antikörper
US11845771B2 (en) 2018-12-27 2023-12-19 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectin and galectin-3
EP4182700A4 (de) * 2020-07-20 2024-11-13 Insmed Incorporated Verfahren zur extraktion neutrophiler serinproteasen und behandlung dipeptidylpeptidase-1-vermittelter erkrankungen

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3625214A (en) 1970-05-18 1971-12-07 Alza Corp Drug-delivery device
US4244946A (en) 1979-06-11 1981-01-13 The Salk Institute For Biological Studies Water-soluble peptides affecting gonadal function
US4305872A (en) 1979-10-19 1981-12-15 Kenneth Wingrove Polypeptide derivatives
US4316891A (en) 1980-06-14 1982-02-23 The Salk Institute For Biological Studies Extended N-terminal somatostatin
US4792525A (en) 1982-08-04 1988-12-20 La Jolla Cancer Research Foundation Tetrapeptide
US4906474A (en) 1983-03-22 1990-03-06 Massachusetts Institute Of Technology Bioerodible polyanhydrides for controlled drug delivery
US4629784A (en) 1983-08-16 1986-12-16 The University Of Georgia Research Foundation, Inc. Synthesis of cyclopropane amino acids
US4752569A (en) * 1984-06-21 1988-06-21 The Regents Of The University Of California Sialylated Lewisx epitope, antibodies and diagnosis
US4783330A (en) * 1984-11-15 1988-11-08 New England Medical Center Hospitals, Inc. Monoclonal antibodies to activated platelets
US4789734A (en) 1985-08-06 1988-12-06 La Jolla Cancer Research Foundation Vitronectin specific cell receptor derived from mammalian mesenchymal tissue
US4904596A (en) * 1985-08-07 1990-02-27 Fred Hutchinson Cancer Research Center Hybridoma antibody (FH6) defining a human cancer-associated difucoganglioside
WO1988001213A1 (en) 1986-08-18 1988-02-25 Clinical Technologies Associates, Inc. Delivery systems for pharmacological agents
US5030723A (en) * 1988-05-31 1991-07-09 The Biomembrane Institute Long-chain glycolipid structure
DK0496832T3 (da) * 1989-10-20 1996-12-30 New England Medical Center Inc Inhibering af PADGEM-formidlet cellebinding

Also Published As

Publication number Publication date
JP2004002444A (ja) 2004-01-08
JP3096305B2 (ja) 2000-10-10
EP0714912B1 (de) 2002-09-25
WO1992001718A2 (en) 1992-02-06
CA2086323A1 (en) 1992-01-18
AU660627B2 (en) 1995-07-06
WO1992001718A3 (en) 1992-05-14
AU8620791A (en) 1992-02-18
ES2183851T3 (es) 2003-04-01
JP2001197899A (ja) 2001-07-24
AU1773195A (en) 1995-07-06
AU697488B2 (en) 1998-10-08
EP0714912A2 (de) 1996-06-05
JP2005255691A (ja) 2005-09-22
EP0544815A1 (de) 1993-06-09
EP0714912A3 (de) 1996-06-26
DE69133120T2 (de) 2003-05-15
JPH05509330A (ja) 1993-12-22
DK0714912T3 (da) 2003-02-03
CA2086323C (en) 2002-05-14
DE69133120D1 (de) 2002-10-31
JPH11147900A (ja) 1999-06-02

Similar Documents

Publication Publication Date Title
DE69133120D1 (de) GMP-140 Ligand
Spiro et al. Structure of the O-glycosidically linked carbohydrate units of fetuin
Cantoni et al. p49, a putative HLA class I‐specific inhibitory NK receptor belonging to the immunoglobulin superfamily
Gabius Animal lectins
Florman et al. O-linked oligosaccharides of mouse egg ZP3 account for its sperm receptor activity
Stamenkovic et al. The B lymphocyte adhesion molecule CD22 interacts with leukocyte common antigen CD45RO on T cells and α2–6 sialyltransferase, CD75, on B cells
Tanaka et al. Serine and threonine glycosidic linkages in bovine submaxillary mucin
Spiro Studies on the renal glomerular basement membrane: Nature of the carbohydrate units and their attachment to the peptide portion
Kornfeld et al. Structure of glycoproteins and their oligosaccharide units
Kobata Structures and functions of the sugar chains of glycoproteins
Kijimoto-Ochiai CD23 (the low-affinity IgE receptor) as a C-type lectin: a multidomain and multifunctional molecule
Labeta et al. Release from a human monocyte‐like cell line of two different soluble forms of the lipopolysaccharide receptor, CD14
Powell et al. Natural ligands of the B cell adhesion molecule CD22 beta carry N-linked oligosaccharides with alpha-2, 6-linked sialic acids that are required for recognition.
Foltz et al. Purification and characterization of an extracellular fragment of the sea urchin egg receptor for sperm.
Matsumoto et al. Structural study of the sugar chains of human lactoferrin: finding of four novel complex-type asparagine-linked sugar chains
Childs et al. Differences in carbohydrate moieties of high molecular weight glycoproteins of human lymphocytes of T and B origins revealed by monoclonal autoantibodies with anti-I and anti-i specificities
Salter-Cid et al. Evolution and developmental regulation of the major histocompatibility complex
Dahms et al. Lymphocyte function-associated antigen 1 (LFA-1) contains sulfated N-linked oligosaccharides.
Samor et al. Preliminary results on the carbohydrate moiety of factor VIII/von Willebrand factor (FVIII/vWf)
Debeire et al. Structure determination of the major asparagine‐linked sugar chain of human factor VII—von Willebrand factor
Hirabayashi A general comparison of two major families of animal lectins
Ettensohn et al. A new method for isolating primary mesenchyme cells of the sea urchin embryo: Panning on wheat germ agglutinin-coated dishes
Sheetz et al. Oxytalan fibers: Identification of the same fiber by light and electron microscopy
Åkerström et al. α1‐Microglobulin Glycopeptides Inhibit Antigen‐Specific Stimulation of Human Peripheral Blood Leucocytes
EP1245575A3 (de) Funktionell aktive selektinderivierte Peptide und Ligand für GMP140

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0714912

Country of ref document: EP

REN Ceased due to non-payment of the annual fee